Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Miami
This phase II study will assess the clinical response rate to Ibritumomab Tiuxetan in patients with untreated nodal, splenic and non-gastric extranodal MZL as well as in antibiotic resistant patients with mucosa-associated lymphoid tissue (MALT) gastric lymphoma.
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥ 18 years old with previously untreated, histologically confirmed Marginal Zone Lymphoma (non-gastric extranodal MZL, splenic MZL and nodal MZL) or gastric MZL that did not respond to antibiotic therapy given up to 6 months prior to enrollment, but not less than 2 months)
Measurable and evaluable disease
All stages are eligible
Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 (Appendix B)
Willing and able to provide written informed consent
Women of childbearing potential must have a negative pregnancy test at study entry and must agree to use effective contraception while on treatment and for 6 months after treatment
Life expectancy of at least 6 months
You may not be if
Prior chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic biologic anticancer therapy before beginning study treatment.
≥ 25% lymphoma bone marrow involvement
Platelet count \< 100,000 cells/mm³
Neutrophil count \< 1,500 cells/mm³
Known history of HIV infection
Pregnant or lactating (pregnancy test is required for all female patients of childbearing potential)
Woman of childbearing potential or sexually active man unwilling to use adequate contraceptive protection.
Physical or mental condition that makes patient unable to complete specified follow-up assessments
Clareo Health | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
